Susquehanna International Group, LLP Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Susquehanna International Group, LLP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	BUY	$38.96 - $42.75 $3.25 Million - $3.57 Million	83,500 Added 20.37%	493,400 $20.2 Million
Q1 2024 May 07, 2024	BUY	$40.88 - $43.27 $2.47 Million - $2.61 Million	60,300 Added 17.25%	409,900 $17.3 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $3.7 Million - $7.74 Million	182,300 Added 108.97%	349,600 $14.8 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $915,752 - $1.44 Million	-45,200 Reduced 21.27%	167,300 $3.65 Million
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $1.08 Million - $1.6 Million	-45,100 Reduced 17.51%	212,500 $6.76 Million
Q1 2023 May 16, 2023	BUY	$22.82 - $35.32 $755,342 - $1.17 Million	33,100 Added 14.74%	257,600 $6.28 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $950,625 - $1.2 Million	-37,500 Reduced 14.31%	224,500 $7.08 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $3.01 Million - $4.89 Million	118,100 Added 82.07%	262,000 $7.4 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $1.41 Million - $2.54 Million	68,500 Added 90.85%	143,900 $3.81 Million
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $1.26 Million - $1.9 Million	-53,700 Reduced 41.6%	75,400 $2.64 Million
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $1.3 Million - $1.98 Million	-44,400 Reduced 25.59%	129,100 $4.19 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $1.29 Million - $2.36 Million	60,700 Added 53.81%	173,500 $5.12 Million
Q2 2021 Aug 11, 2021	BUY	$12.56 - $29.69 $1.42 Million - $3.35 Million	112,800 New	112,800 $2.89 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.